Akero’s Phase II Success Could Augur Brighter Days For NASH R&D

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

With Akero’s FGF21 analog showing ability to reduce fibrosis and resolve non-alcoholic steatohepatitis, some analysts think classmate BIO89-100 could yield a better overall profile. NASH data are starting to pour in.

NASH race
Akero is emerging as a co-favorite with Madrigal in NASH R&D • Source: Shutterstock

Akero Therapeutics, Inc.’s successful Phase IIb data with efruxifermin (EFX) in pre-cirrhotic non-alcoholic steatohepatitis (NASH) patients provided good news for the company, but also more generally for the NASH space, which has been mostly dominated by trial failures and regulatory setbacks during the past two years. In addition, EFX’s ability to reduce fibrosis and resolve NASH in the Phase IIb HARMONY trial also was considered reason for optimism for Akero’s direct competitor, 89bio, Inc.

[Sidebar#SC147063]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.